Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1501 AL 1515

Regulation of tau by peptidyl-prolyl isomerases

Zhuang S, Chakraborty P, Zweckstetter M.

Curr Opin Struct Biol. 2024 Feb;84:102739. doi: 10.1016/j.sbi.2023.102739. Epub 2023 Dec 7.

Understanding Glycogen Synthase Kinase-3: A Novel Avenue for Alzheimer's Disease

Sequeira RC, Godad A.

Mol Neurobiol. 2024 Jul;61(7):4203-4221. doi: 10.1007/s12035-023-03839-1. Epub 2023 Dec 8.

Once upon a time, the Amyloid Cascade Hypothesis

Granzotto A, Sensi SL.

Ageing Res Rev. 2024 Jan;93:102161. doi: 10.1016/j.arr.2023.102161. Epub 2023 Dec 6.

Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer's disease in a rat/mouse model: a systematic review

Khalifa MKA, Abdel-Sattar SA, Amin OM, Kohaf NA, Zaky HS, Abd El-Fattah MA, Mohammed KHA, Badawi NM, Mansoor I, Eassa HA.

Daru. 2024 Jun;32(1):319-337. doi: 10.1007/s40199-023-00494-8. Epub 2023 Dec 11.

A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease

Lannfelt L.

Ups J Med Sci. 2023 Nov 28;128. doi: 10.48101/ujms.v128.10316. eCollection 2023.

Piecing together the Alzheimer's puzzle: Lecanemab's role in treatment

Ashraf DA, Tariq H, Hassan FS, Kamran F, Khosa WM, Khosa MM.

Neurodegener Dis Manag. 2023 Oct;13(5):257-259. doi: 10.2217/nmt-2023-0026. Epub 2023 Dec 12.

Unravelling the in vitro and in vivo potential of selenium nanoparticles in Alzheimer's disease: A bioanalytical review

Vicente-Zurdo D, Rosales-Conrado N, León-González ME.

Talanta. 2024 Mar 1;269:125519. doi: 10.1016/j.talanta.2023.125519. Epub 2023 Dec 7.

Biomembrane-Derived Nanoparticles in Alzheimer's Disease Therapy: A Comprehensive Review of Synthetic Lipid Nanoparticles and Natural Cell-Derived Vesicles

Gao C, Liu Y, Zhang TL, Luo Y, Gao J, Chu JJ, Gong BF, Chen XH, Yin T, Zhang J, Yin Y.

Int J Nanomedicine. 2023 Dec 7;18:7441-7468. doi: 10.2147/IJN.S436774. eCollection 2023.

Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease

Park J, Simpson C, Patel K.

Ann Pharmacother. 2024 Oct;58(10):1045-1053. doi: 10.1177/10600280231218253. Epub 2023 Dec 14.

Lecanemab: More Questions Than Answers!

Kaur U, Reddy J, Tiwari A, Chakrabarti S, Chakrabarti SS.

Clin Drug Investig. 2024 Jan;44(1):1-10. doi: 10.1007/s40261-023-01331-1. Epub 2023 Dec 14.

Cancer drugs with high repositioning potential for Alzheimer's disease

Majeed J, Sabbagh MN, Kang MH, Lawrence JJ, Pruitt K, Bacus S, Reyna E, Brown M, Decourt B.

Expert Opin Emerg Drugs. 2023 Dec;28(4):311-332. doi: 10.1080/14728214.2023.2296079. Epub 2023 Dec 26.

Machine learning in Alzheimer's disease drug discovery and target identification

Geng C, Wang Z, Tang Y.

Ageing Res Rev. 2024 Jan;93:102172. doi: 10.1016/j.arr.2023.102172. Epub 2023 Dec 16.

Tau and Alzheimer's disease: Past, present and future

Iqbal K.

Cytoskeleton (Hoboken). 2024 Jan;81(1):116-121. doi: 10.1002/cm.21822. Epub 2023 Dec 21.

Curcumin hybrid molecules for the treatment of Alzheimer's disease: Structure and pharmacological activities

Zang WB, Wei HL, Zhang WW, Ma W, Li J, Yao Y.

Eur J Med Chem. 2024 Feb 5;265:116070. doi: 10.1016/j.ejmech.2023.116070. Epub 2023 Dec 18.

Caspases in Alzheimer's Disease: Mechanism of Activation, Role, and Potential Treatment

Wójcik P, Jastrzębski MK, Zięba A, Matosiuk D, Kaczor AA.

Mol Neurobiol. 2024 Jul;61(7):4834-4853. doi: 10.1007/s12035-023-03847-1. Epub 2023 Dec 23.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias